Dataset Information

Comprehensive metaboproteomics of Burkitt’s and diffuse large B-cell lymphoma cell lines and primary tumor tissues

ABSTRACT: Comparative proteome analysis of BL and DLBCL cell lines, cryopreserved and formalin-fixed paraffin-embedded (FFPE) primary tumor specimens by SWATH-MS.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Primary Cell, Cell Culture

DISEASE(S): Lymphoma

SUBMITTER: Philipp Schwarzfischer

LAB HEAD: Prof. Dr. Peter Oefner

PROVIDER: PXD004936 | Pride | 2017-02-08

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	150511Schwarzfischer_tissue1.wiff	Wiff
	150511Schwarzfischer_tissue1.wiff.scan	Wiff
	150511Schwarzfischer_tissue10.wiff	Wiff
	150511Schwarzfischer_tissue10.wiff.scan	Wiff
	150511Schwarzfischer_tissue11.wiff	Wiff

Items per page:

1 - 5 of 151

Publications

Comprehensive Metaboproteomics of Burkitt's and Diffuse Large B-Cell Lymphoma Cell Lines and Primary Tumor Tissues Reveals Distinct Differences in Pyruvate Content and Metabolism.

Schwarzfischer Philipp P Reinders Jörg J Dettmer Katja K Kleo Karsten K Dimitrova Lora L Hummel Michael M Feist Maren M Kube Dieter D Szczepanowski Monika M Klapper Wolfram W Taruttis Franziska F Engelmann Julia C JC Spang Rainer R Gronwald Wolfram W Oefner Peter J PJ

Journal of proteome research 20170216 3

Burkitt's lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) are pathologically and clinically distinct subtypes of aggressive non-Hodgkin B-cell lymphoma. To learn more about their biology, we employed metabolomic and proteomic methods to study both established cell lines as well as cryopreserved and formalin-fixed paraffin-embedded (FFPE) tissue sections of BL and DLBCL. Strikingly, NMR analyses revealed DLBCL cell lines to produce and secrete significantly (p<sub>adj</sub> = 1.72 × 10<su ...[more]

PMID: 28161958

Similar Datasets

Project description:Sporadic Burkitt lymphoma (sBL) can be delineated from diffuse large B-cell lymphoma (DLBCL) by a very homogeneous mRNA expression signature. However, it remained unclear whether all three BL variants – sBL, endemic BL (eBL) and immunodeficiency-associated BL (HIV-BL) – represent a uniform biological entity despite their differences in geographical occurrence, association with immunodeficiency and/or incidence of EBV infection. To address this issue, we generated micro RNA (miRNA) profiles from 18 eBL, 31 sBL and 15 HIV-BL cases. In addition, we analyzed the miRNA expression of 86 DLBCL to determine whether miRNA profiles recapitulate the molecular differences between BL and DLBCL evidenced by mRNA profiling. A signature of 38 miRNAs enriched in MYC regulated and NF-kB pathway associated miRNAs was obtained that differentiated BL from DLBCL. The miRNA profiles of sBL and eBL displayed only 6 differentially expressed miRNAs, whereas HIV and EBV infection had no impact on the miRNA profile of BL. In conclusion, miRNA profiling confirms that BL and DLBCL represent distinct lymphoma categories and demonstrates that the three BL variants are representatives of the same biological entity with only marginal miRNA expression differences between eBL and sBL. Archival tumor specimens of 86 diffuse large B-cell lymphoma (DLBCL) and 64 Burkitt lymphoma (BL) patients were obtained. The DLBCL samples have previously been reviewed by a panel of expert hematopathologists and their clinical data were published as part of the RiCOVER-60 trial. The diagnosis of all BL cases was confirmed by histopathology review according to the criteria of the WHO classification. Based on their geographical origin, 31 BL samples were designated as sporadic BL (sBL) and 18 samples as endemic BL (eBL). Fifteen BL cases were diagnosed as immunodeficiency-associated BL (HIV-BL). Of the 18 eBL 14 cases were EBV+ (87.5%), 2 samples were EBV- (12.5%) and for 2 eBL cases the EBV status was unknown. Of the sBL samples 26 were EBV- (86.7%), 4 cases were EBV+ (13.3%) and for 1 case the EBV status was not evaluable. Among the HIV-BL 5 (33.3%) were EBV+, whereas 10 (66.7%) were EBV-.